A Venture Capital firm based in San Francisco California. The firm is interested in making equity investments into early-stage companies with investments ranging from $1M to $15 million per company, depending on the companies needs and stage of development. The firm is currently seeking investment opportunities throughout the United States.

The firm is looking for companies operating in the HIT/ Digital Health space as well as diagnostics and devices with a software component. The firm is entirely opportunistic in terms of indication and will consider companies at all stages of development. Specific areas of interest include life science tools, mental health, digital therapeutics, synthetic biology and 3D printing.

The firm is looking for privately held companies with strong management teams. The firm is able to provide entrepreneurs with a 200-person advisory network and bring deep operational expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

A Dallas, Texas based VC firm that was founded in 2011 and is focused on healthcare companies. The firm makes seed, venture, and growth stage investments. The firm typically provides seed and Series A equity financing in the range of $100K to $1M per portfolio company. The firm generally acts as the lead investor and is open to investing in syndicates. The firm primarily invests in companies that are based in Texas but is open to opportunities across North America. The firm is actively seeking new investment opportunities.

The firm is currently seeking to invest in medical devices, diagnostics, digital health, and software. The firm is also interested in reformulated and repurposed drugs that have mitigated risk. For medical devices, the firm is opportunistic in terms of subsectors. Ideally, the product has a prototype and 510(k) regulatory pathway. The firm is open to investing in any indication, including orphan diseases; the dental field is of interest.

The firm seeks a strong and experienced management team. The firm may take a board seat where appropriate.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

A newly founded investment firm based in Melbourne, Australia. The firm manages an open-ended, evergreen fund that focuses on life science investments. The firm invests in both early-stage and late-stage companies with a slight focus on the latter. In early-stage companies, the size of initial investment is between $1-5M. The firm is a provider of continuous capital and will continue to support portfolio companies through follow-on investments (provided milestones are met). The firm is open to global investments and does not require an Australia angle.

The firm invests broadly across the life sciences, including therapeutics, medical devices, diagnostics, digital health, and ag-bio, with 4 key investment themes that they closely navigate. The 4 themes are (1) personalized/precision medicine (i.e. NGS, big data), (2) infectious diseases and drug resistance (i.e. vaccines, anti-bacterials, rapid diagnostics), (3) “healthspan” (i.e. preventative and regenerative medicine, wellness, anything that slows the aging process, chronic diseases and age-related diseases), and (4) feeding the world (i.e. sustainable proteins, biological solutions for farmers, water and air purification technologies). The firm is stage agnostic and will consider technologies that are as early as pre-PoC.

The firm seeks to work with companies with innovative, highly disruptive technologies in the biotech/medical space. The firm is an active investor, meaning that the firm will work closely with portfolio companies to support their growth post-initial investment. The firm’s team has a broad range of experience in life sciences investments, funds management, international business development, etc., through which the firm provides strategic support. The firm prefers to lead and seek board representation, but this is not always the case.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

A global firm with offices worldwide invests in medical technology companies that are strategically relevant to its parent company. The firm invests in new technologies via venture investing, collaborations, incubation, or M&A. The firm invests worldwide.

The firm’s primary focuses within healthcare include in-vitro diagnostics (particularly immuno and molecular diagnostics), digital lab services (including capacity management, care coordination, technologies that help physicians make diagnoses and other key decisions) and AI technologies in healthcare. The firm will invest in any medical indication area, and prefers companies that have at least attained proof of concept data or with a product on market demonstrating traction and revenue.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.